Governor Signs Ibogaine Treatment Research into Law

Translate to Spanish or other 102 languages!

Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. Photo: Office of The Governor
Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. Photo: Office of The Governor
- Advertisement -

AUSTIN — Governor Greg Abbott signed Senate Bill 2308 into law to grant state matching funds for research of ibogaine as an emerging treatment for neurological and mental health conditions during a bill signing ceremony at the Texas Capitol. 

“Texas is home to more veterans than any other state,” said Governor Abbott. “Many of those veterans suffer from injuries both seen and unseen. A therapy that has shown great promise in treating those conditions is ibogaine. This law authorizes a Food and Drug Administration approved clinical drug trial that will seek approval of ibogaine as a medication for the treatment of opioid use disorder and other behavioral health conditions, especially those suffered by our veterans. Texas will now lead the way in America for the evaluation of ibogaine as a potential medication that can help improve the lives of so many veterans.” 

View the Governor’s full bill signing ceremony here.

- Advertisement -

The Governor was joined at the bill signing ceremony by Speaker Dustin Burrows, Senator Tan Parker, Senator Charles Perry, and dozens of Texas supporters.

Ibogaine is a plant-based, psychoactive substance that can help treat opioid use disorder, depression, and post-traumatic stress disorder. Senate Bill 2308 allows the Texas Health and Human Services Commission to provide state matching funds for a Food and Drug Administration drug trial managed by a public university in partnership with a drug company and hospital.

Senate Bill 2308 (Parker/Harris) authorizes clinical drug trials on ibogaine to research the potential for treatment of opioid use disorder, depression, and post-traumatic stress disorder.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Exploring Facial Processing Differences in Autism

Some of the hallmark characteristics of autism are the tendencies to avoid looking at other’s faces and making less eye contact.

STHS’ Freestanding ERs Earn National Recognition for High-Quality Resuscitation Care

Sudden cardiac arrest is a life-threatening medical emergency that occurs when the heart unexpectedly stops beating, abruptly cutting off blood flow to the brain and other vital organs. It can strike anyone, at any age, often without warning.

New Lancet Commission Outlines Roadmap to Close the Gender Gap in Blood Disorders

A new report in The Lancet Haematology, led by Cleveland Clinic hematologist Bethany Samuelson Bannow, M.D., outlines practical strategies to improve diagnosis, care and outcomes globally for women and girls with hematological conditions, such as bleeding disorders, heavy menstrual bleeding, postpartum hemorrhage, thrombosis and maternal hematologic complications.

DHR Health Neuroscience Institute Nationally Recognized for Commitment to Excellence in Stroke Care

DHR Health Neuroscience Institute received the American Heart Association’s Get With The Guidelines® - Stroke Gold Plus quality achievement award for its commitment to ensuring people experiencing a stroke receive timely, appropriate treatment based on nationally recognized, research-based guidelines, ultimately helping to save lives and reduce disability.
- Advertisement -